Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;16(8):1319-31.
doi: 10.1007/s00894-010-0647-2. Epub 2010 Feb 1.

Evaluation of molecular descriptors and HPLC retention data of analgesic and anti-inflammatory drugs by factor analysis in relation to their pharmacological activity

Affiliations

Evaluation of molecular descriptors and HPLC retention data of analgesic and anti-inflammatory drugs by factor analysis in relation to their pharmacological activity

Marcin Koba et al. J Mol Model. 2010 Aug.

Abstract

Factor analysis (FA) was performed for some analgesic, anti-inflammatory and antipyretic drugs to model relationships between molecular descriptors and HPLC retention parameters. FA performed using 26 sets of structural parameters, 26 sets of HPLC retention data, and considering all parameters together (52 parameters) led to the extraction of two main factors. The first principal component (factor 1) accounted for 65-73% of the variance in the data. The second principal component (factor 2) explained 27-35% of data variance. Moreover, of the 52 parameters tested, the highest influence on factor value was found with chromatographic parameters and selected structural parameters (i.e., energy quantum-chemical parameters and electron affinity specifying parameters). Additionally, the pattern of distribution of individual drugs within the plane determined by the two principal components (factors 1 and 2) was in good agreement with their pharmacological (analgesic, anti-inflammatory and antipyretic) properties. The findings are discussed from the point of view of structure-activity relationships.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Pharm Ther. 2008 Apr;33(2):101-8 - PubMed
    1. Med Res Rev. 1987 Jan-Mar;7(1):1-28 - PubMed
    1. Clin Ther. 2002 Aug;24(8):1225-91 - PubMed
    1. Inflammopharmacology. 2006 Aug;14(3-4):120-37 - PubMed
    1. J Chromatogr. 1991 Jul 26;550(1-2):573-84 - PubMed

MeSH terms

LinkOut - more resources